Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Autologous B cells and monocytes transfected with E6E7 gene of HPV”In the company’s words, NCT02866006 on ClinicalTrials.gov
- Tested for
- Uterine Cervical Neoplasms
- Main trialPhase 1/2
- “BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.”In the company’s words, NCT02866006 on ClinicalTrials.gov
Other drugs for Uterine Cervical Neoplasms
- SocazolimabLee's Pharmaceutical Limited · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- JSKN033Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase 3
- Bulumtatug fuvedotinMabwell · Phase 3
- SHR-A2102Hengrui · Phase 3
- SYS6002CSPC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | Dec 2021 | Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026